Recombinant Anti-Nicotinic Acetylcholine Receptor alpha 4/CHRNA4 antibody [EPR4563(2)] (ab124832)
![Western blot - Anti-Nicotinic Acetylcholine Receptor alpha 4/CHRNA4 antibody [EPR4563(2)] (ab124832)](https://www.abcam.com/ps/products/124/ab124832/Images/ab124832-138781-anti-nicotinic-acetylcholine-receptor-alpha-4-antibody-epr45632-western-blot.jpg "Western blot - Anti-Nicotinic Acetylcholine Receptor alpha 4/CHRNA4 antibody [EPR4563(2)] (ab124832)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR4563(2)] to Nicotinic Acetylcholine Receptor alpha 4/CHRNA4
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
Overview
-
Product name
Anti-Nicotinic Acetylcholine Receptor alpha 4/CHRNA4 antibody [EPR4563(2)]
See all Nicotinic Acetylcholine Receptor alpha 4/CHRNA4 primary antibodies -
Description
Rabbit monoclonal [EPR4563(2)] to Nicotinic Acetylcholine Receptor alpha 4/CHRNA4 -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: Flow Cyt,ICC or IHC-P -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide within Human Nicotinic Acetylcholine Receptor alpha 4/CHRNA4 aa 500-600. The exact sequence is proprietary.
-
Positive control
- SH-SY5Y, A673, C6 and Neuro-2a cell lysates.
-
General notes
This product was previously labelled as Nicotinic Acetylcholine Receptor alpha 4
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading... -
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
EPR4563(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab124832 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | 1/10000 - 1/50000. Detects a band of approximately 70 kDa (predicted molecular weight: 70 kDa). |
Target
-
Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. -
Involvement in disease
Defects in CHRNA4 are the cause of nocturnal frontal lobe epilepsy type 1 (ENFL1) [MIM:600513]; also symbolized ADNFLE. ENFL1 is an autosomal dominant epilepsy characterized by nocturnal seizures with hyperkinetic automatisms and poorly organized stereotyped movements. -
Sequence similarities
Belongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Alpha-4/CHRNA4 sub-subfamily. -
Cellular localization
Cell junction > synapse > postsynaptic cell membrane. Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 1137 Human
- Entrez Gene: 11438 Mouse
- Entrez Gene: 25590 Rat
- Omim: 118504 Human
- SwissProt: P43681 Human
- SwissProt: O70174 Mouse
- SwissProt: P09483 Rat
- Unigene: 10734 Human
see all -
Alternative names
- A4 nicotinic receptor antibody
- Acetylcholine receptor alpha 4 neural antibody
- Acetylcholine receptor neuronal nicotinic alpha 4 subunit antibody
see all
Images
-
Western blot - Anti-Nicotinic Acetylcholine Receptor alpha 4/CHRNA4 antibody [EPR4563(2)] (ab124832)All lanes : Anti-Nicotinic Acetylcholine Receptor alpha 4/CHRNA4 antibody [EPR4563(2)] (ab124832) at 1/10000 dilution
Lane 1 : SH-SY5Y cell lysate
Lane 2 : A673 cell lysate
Lane 3 : C6 cell lysate
Lane 4 : Neuro-2a cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 70 kDa
Observed band size: 70 kDa -
![Anti-Nicotinic Acetylcholine Receptor alpha 4/CHRNA4 antibody [EPR4563(2)] (ab124832)](https://www.abcam.com/ps/products/124/ab124832/Images/ab124832-2-benefits-of-recombinant-antibodies.png)
Anti-Nicotinic Acetylcholine Receptor alpha 4/CHRNA4 antibody [EPR4563(2)] (ab124832)
Protocols
Datasheets and documents
References (4)
ab124832 has been referenced in 4 publications.
- Sun Z et al. Differential Expression of Nicotine Acetylcholine Receptors Associates with Human Breast Cancer and Mediates Antitumor Activity of aO-Conotoxin GeXIVA. Mar Drugs 18:N/A (2020). PubMed: 31963558
- Liu Y et al. Cervical Cancer Correlates with the Differential Expression of Nicotinic Acetylcholine Receptors and Reveals Therapeutic Targets. Mar Drugs 17:N/A (2019). PubMed: 31035425
- Chen SP et al. Involvement of hippocampal acetylcholinergic receptors in electroacupuncture analgesia in neuropathic pain rats. Behav Brain Funct 12:13 (2016). PubMed: 27068709
- Yin Y et al. Accumulation of human full-length tau induces degradation of nicotinic acetylcholine receptor a4 via activating calpain-2. Sci Rep 6:27283 (2016). WB . PubMed: 27277673
